References
- 1
Sharma P, McQuaid K, Dent J. et al .
AGA Chicago Workshop. A critical review of the diagnosis and management of Barrett’s
esophagus: the AGA Chicago Workshop.
Gastroenterology.
2004;
127
310-330
- 2
Devesa S S, Blot W J, Fraumeni J F Jr.
Changing patterns in the incidence of esophageal and gastric carcinoma in the United
States.
Cancer.
1998;
83
2049-2053
- 3
Blot W J, Devesa S S, Fraumeni J F Jr.
Continuing climb in rates of esophageal adenocarcinoma: an update.
JAMA.
1993;
270
1320
- 4
Pera M, Cameron A J, Trastek V F. et al .
Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction.
Gastroenterology.
1993;
104
510-513
- 5
Pohl H, Welch H G.
The role of overdiagnosis and reclassification in the marked increase of esophageal
adenocarcinoma incidence.
J Natl Cancer Inst.
2005;
97
142-146
- 6
Daly J M, Karnell L H, Menck H R.
National Cancer Data Base report on esophageal carcinoma.
Cancer.
1996;
78
1820-1828
- 7
Provenzale D, Kemp J A, Arora S, Wong J B.
A guide for surveillance of patients with Barrett's esophagus.
Am J Gastroenterol.
1994;
89
670-680
- 8
Jolly A J, Wild C P, Hardie L J.
Acid and bile salts induce DNA damage in human esophageal cell lines.
Mutagenesis.
2004;
19
319-324
- 9
Kaur B S, Triadafilopoulos G.
Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett’s esophagus
are COX-2 and PKC-epsilon dependent.
Am J Physiol.
2002;
283
G327-G334
- 10
Sital R R, de Rooij F W, Kusters J G. et al .
Barrett’s esophagus is associated with reflux of secondary bile acids into the esophagus.
Gastroenterology.
2005;
128
A-34
- 11
Sampliner R E,. Practice Parameters Committee of the American College of Gastroenterology
.
Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus.
Am J Gastroenterol.
2002;
97
1888-1895
- 12
Shaheen N, Ransohoff D F.
Gastroesophageal reflux, barrett’s esophagus, and esophageal cancer: scientific review.
JAMA.
2002;
287
1972-1981
- 13
Stoltey J, Ullah N, Sahbaie P. et al .
Does Barrett’s esophagus develop over time in patients with chronic GERD.
Gastrointest Endosc.
2005;
61
AB103
- 14
Soni A, Sampliner R E, Sonnenberg A.
Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?.
Am J Gastroenterol.
2000;
95
2086-2093
- 15
Inadomi J M, Sampliner R, Lagergren J. et al .
Screening and surveillance for Barrett esophagus in high-risk groups: a cost- utility
analysis.
Ann Intern Med.
2003;
138
176-186
- 16
Atkinson M, Das A, Faulx A. et al .
Unsedated screening esophagoscopy for Barrett’s esophagus in a primary care VA setting.
Gastrointest Endosc.
2005;
61
AB127
- 17
Ramirez F C, Akins R, Shaukat M.
String capsule endoscopy for the screening of Barrett’s esophagus in patients with
chronic GERD: a prospective blinded study.
Gastrointest Endosc.
2005;
61
AB141
- 18
Falk G W.
Barrett’s esophagus.
Gastroenterology.
2002;
122
1569-1591
- 19
Borovicka J, Fischer J, Neuweiler J. et al .
Role of autofluorescence endoscopy in surveillance of Barrett’s esophagus: a prospective
multicenter randomized trial.
Gastrointest Endosc.
2005;
61
AB103
- 20
Haringsma J, Poley J, Blok P. et al .
Detection of intraepithelial neoplasia in Barrett’s esophagus using autofluorescence
endoscopy.
Gastroenterology.
2005;
128
A-52
- 21
Sharma P, Bansal A, Rastogi A. et al .
The utility of a novel narrow band imaging (NBI) endoscopy system in patients with
Barrett’s esophagus (BE).
Gastrointest Endosc.
2005;
61
AB240
- 22
Kara M, Peters F, Fockens P. et al .
Video autofluorescence imaging (AFI) followed by narrow band imaging (NBI) for detection
of high grade intraepithelial neoplasia (HGIN) in Barrett’s esophagus (BE).
Gastroenterology.
2005;
128
A-51
- 23
Wang K K, Halling K, Brankley S. et al .
The prospective evaluation of fluorescent in situ hybridization (fish) for the detection
of dysplasia and adenocarcinoma in Barrett’s esophagus.
Gastroenterology.
2005;
128
A-34
- 24
Borovicka J, Schonegg R, Kradolfer D. et al .
Combined digital image cytometry with fluorescence in situ hybridization of brush
cytology identifies patients with Barrett’s esophagus at increased risk for neoplastic
progression.
Gastrointest Endosc.
2005;
61
AB103
- 25
Reid B J, Prevo L J, Galipeau P C. et al .
Predictors of progression in Barrett"s esophagus II: baseline 17p (p53) loss of heterozygosity
identifies a patient subset at increased risk for neoplastic progression.
Am J Gastroenterol.
2001;
96
2839-2848
- 26
Bani-Hani K, Martin I G, Hardie L J. et al .
Prospective study of cyclin D1 overexpression in Barrett’s esophagus: association
with increased risk of adenocarcinoma.
J Natl Cancer Inst.
2000;
92
1316-1321
- 27
Sampliner R E, Fennerty B, Garewal H S.
Reversal of Barrett’s esophagus with acid suppression and multipolar electrocoagulation:
preliminary results.
Gastrointest Endosc.
1996;
44
532-535
- 28
Sharma P, Weston A, Hall M. et al .
A randomized controlled trial of ablation of Barrett’s esophagus with electrocautery
vs argon plasma coagulation: long term results.
Gastrointest Endosc.
2005;
61
AB94
- 29
Eisen G M.
Ablation therapy for Barrett’s esophagus.
Gastrointest Endosc.
2003;
58
760-769
- 30
Reid B J, Levine D S, Longton G. et al .
Predictors of progression to cancer in Barrett’s esophagus: baseline histology and
flow cytometry identify low- and high-risk patient subsets.
Am J Gastroenterol.
2000;
95
1669-1676
- 31
Heitmiller R F, Redmond M, Hamilton S R.
Barrett’s esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy.
Ann Surg.
1996;
224
66-71
- 32
Falk G W, Rice T W, Goldblum J R. et al .
Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus
with high grade dysplasia.
Gastrointest Endosc.
1999;
49
170-176
- 33
Swisher S G, DeFord L, Merriman K W. et al .
Effects of operative volume on morbidity, mortality, and hospital use after esophagectomy
for cancer.
J Thorac Cardiovasc Surg.
2000;
119
1126-1134
- 34
Mackenzie G, Clark B R, Selvasekar C. et al .
Photodynamic therapy with 5 Aminolevulinic acid for high grade dysplasia in Barrett’s
esophagus: long term follow up in 51 patients.
Gastroenterology.
2005;
128
AB238
- 35
Wang K, Buttar N, Wongkeesong M. et al .
Should complete ablation of Barrett’s esophagus (BE) be the goal of photodynamic therapy
(PDT)?.
Gastrointest Endosc.
2005;
61
AB94
- 36
Pech O, May A, Gossner L. et al .
Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer).
Gastrointest Endosc.
2005;
61
AB140
- 37
Cameron A J, Carpenter H A.
Barrett’s esophagus, high-grade dysplasia, and early adenocarcinoma: A pathological
study.
Am J Gastroenterol.
1997;
92
586-591
- 38
Peters F, Kara M, Rosmolen W. et al .
Barrett’s esophagus (BE) with high grade dysplasia (HGD) and/or early cancer (EC):
stepwise radical endoscopic resection (SRER) for complete removal of the BE is safe
and effective.
Gastrointest Endosc.
2005;
61
AB140
P. Sharma, M. D.
University of Kansas, Gastroenterology Section - 111, VA Medical Center
4801 E Linwood Blvd · Kansas City · Missouri 64128 · USA
Fax: 01-816-922-4692
eMail: psharma@kumc.edu
